While both cell lines were derived from aggressive HER2+ breast cancers, the treatment protocols each patient received likely contributed to the overall behavior of the resultant cell lines in culture beyond the obvious sensitivity or resistance to HER2 inhibitors. Here, ERBB2 is linked to breast carcinoma.